Industrial cyclicality + a full multiple: a destocking / recession hit lands on 35× trailing earnings
One-line thesis. Parker-Hannifin is a best-in-class diversified-industrial compounder — record 23%+ segment margins, 70 straight years of dividend increases, a record $12.5B backlog and an accelerating aerospace franchise — but at $963 it already trades near our base-case fair value (~$1,010) and slightly above where the aftermarket-cyclical earnings power justifies, so we rate it Watch and would want a better entry.
◆ Synthos call — HoldPH is a solid business largely reflected at ~$1,010 — fine to keep, no reason to chase; it gets interesting again below ~$858.
Downside Risk (lower = safer)
6/10 · High
Fortress-ish (net-debt/EBITDA 1.6×, IG credit) but 35× trailing / 28× forward on ~7% revenue growth, cyclical, plus a debt-funded Filtration Group deal pending.
Growth Quality
6/10 · High
~7% forward revenue CAGR, ~10% EPS CAGR, record 23%+ segment margins & 25% ROE — durable quality, not fast growth.
Exponential Potential
3/10 · Low
$121B cap, growth steady-to-decelerating; only the aerospace super-cycle accelerates — mature compounder, limited multibagger room.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 27%/yrTo justify today’s $963, earnings would have to compound roughly 27% a year for 10 years (9% discount rate). Analysts forecast ~12%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Parker-Hannifin makes the "plumbing and muscles" of machines — the hydraulic pumps, valves, filters, seals, and motion systems that go inside factory equipment, construction and farm machinery, and airplanes. It is a quiet, century-old giant: not a household name, but its parts are in almost everything that moves.
The business is genuinely excellent — very profitable, steadily growing, and it has raised its dividend for 70 years in a row. The problem is the price. The stock has run up a lot, and at today's level you're paying about $35 for every $1 the company earns — a full price for a company growing earnings only around 10% a year. Our fair-value estimate (~$1,010) is barely above today's $963, so there isn't much of a bargain here.
Our verdict is Watch: a wonderful company, but wait for a cheaper entry (a market pullback would help).
Here's what our three scores mean in everyday terms:
Downside Risk 6/10 (a bit above average). The company is financially solid, but it's cyclical — when factories slow down, so does Parker — and it's priced high, so a stumble would hurt.
Growth Quality 6/10 (good, not great). Steady mid-single-digit sales growth, fat margins, strong returns — a reliable grower rather than a rocket.
Exponential Potential 3/10 (low). It's already huge and growing at a mature pace, so don't expect it to double quickly.
The one big worry: Parker's fortunes rise and fall with the industrial economy. A recession or a slowdown in factory spending would dent earnings, and that would land on an already-expensive stock.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago
Solid = PH · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$962.89
Market cap$121B
P/E trailing42×
P/E FY26E / FY27E31× / 28×
EV / Sales6.2×
EV / EBITDA23.2×
Gross margin37.2%
Net margin16.6%
Dividend yield0.77%
Beta1.11
52-wk range$697 – $1,023
RSI(14)68
50 / 200-DMA$906 / $886
12-mo return+37% (SPY +21%)
Street target$1,057 ($950–$1,269)
Analyst grades24 Buy · 13 Hold · 1 Sell
FMP ratingB+
Next earnings2026-08-05
What the experts actually said 0 traceable claims on PH · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Parker-Hannifin (NYSE: PH) is a ~108-year-old (founded 1917, HQ Cleveland, OH) global leader in motion and control technologies — hydraulics, pneumatics, electromechanical systems, filtration, sealing, fluid connectors, and aerospace flight/engine systems. It sells to OEMs and to a large, higher-margin aftermarket through its own sales force plus distributors. Fiscal year ends June 30. CEO: Jennifer (Jenny) Parmentier.
The company runs on "The Win Strategy" — a lean-operating playbook that has structurally lifted margins over the past decade — and has transformed itself from a pure short-cycle industrial into a higher-quality, longer-cycle business via large acquisitions (Clarcor, LORD, Meggitt aerospace).
Revenue mix (FY2025, from filings):
By segment: Diversified Industrial $13.67B (69%) · Aerospace Systems $6.19B (31%). Aerospace is the growth engine now — FY26 Q3 aerospace sales grew +15.5% (+14.2% organic) on commercial OEM and aftermarket strength, vs low-single-digit organic in industrial.
By geography: North America $13.41B (68%) · Europe $3.86B (19%) · Asia Pacific $2.36B (12%) · Latin America $0.22B (1%). Predominantly a North America / developed-market business.
The strategic story to watch: (a) the aerospace super-cycle (record backlog, defense + commercial OEM/aftermarket), and (b) the pending acquisition of Filtration Group Corporation plus integration of Curtis Instruments — bolt-ons that add long-cycle, aftermarket-rich revenue but also add leverage.
2. The expert thesis
There is no expert coverage of Parker-Hannifin in the Synthos knowledge base.total_claims = 0, net_bullish_voices = 0. No fund manager, analyst, or podcast in our tracked panel has made a traceable claim on PH.
That is an honest limitation, not a hidden signal. This verdict is entirely fundamentals- and quant-driven — built from the financial statements, analyst consensus estimates (FMP), management's own SEC-filed guidance (half-weighted, §9), and our scenario model (§3). No conviction is borrowed from voices that do not exist in our KB. Where the LLY-style notes cite claim_ids, this note deliberately cites none, because there are none to cite.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
6 · Above-average
Financially sturdy (net-debt/EBITDA 1.6×, IG credit, 10.8× interest coverage, ROE 25%), but 35× trailing / ~28× forward is a full multiple on a cyclical ~7%-grower, beta 1.11, and the debt-funded Filtration Group deal adds leverage.
Growth Quality
6 · Good
~7% forward revenue CAGR, ~10% EPS CAGR, record 23.9% segment margins, 25% ROE, 13% ROIC, 70-year dividend streak — durable, high-quality compounding, but not fast.
Exponential Potential
3 · Low
$121B cap; growth is steady-to-decelerating (industrial mature; only aerospace accelerating). No multibagger runway from here — a compounder, not an exponential.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
Estimates roughly hit — FY27E EPS ~$34; a durable high-quality industrial compounder earns ~29–30× in a strong aero cycle.
~$1,010 (+5%)
Bear
Industrial destocking / recession; aero cycle rolls; margin give-back and deal-integration friction. FY27E EPS ~$31; multiple de-rates to ~24×.
~$760 (−21%)
Synthos fair value = the base case, ~$1,010 (+5%), with the full $760–$1,180 span as the honest range. Our base sits just below the Street's $1,057 target — the stock has largely caught up to fair value, which is why the verdict is Watch, not Buy. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). PH is a high-quality compounder that is nowhere near exponential:
Acceleration (the 2nd derivative) is mixed-to-negative at the top line: consolidated organic sales grew only ~6.5% in FY26 Q3, and FY26 guidance implies ~5.5% organic. The one accelerating piece is Aerospace (+14% organic, +14% orders, record backlog) — but it's 31% of revenue, not enough to make the whole company accelerate. Industrial short-cycle is steady, not springing.
Room to run: at $121B market cap in a mature, competitive motion-and-control market, there is no realistic path to a multibagger. A 3× from here implies a ~$360B industrial — larger than any pure-play peer today. PH compounds mid-teens total return in a good cycle; it does not multiply quickly.
Reinvestment runway: disciplined — modest capex (~2% of sales), M&A-led reinvestment (Filtration Group), and heavy cash return (dividends + buybacks). A great capital-allocation story, not a reinvestment-at-high-incremental-returns growth story.
Exponential Potential: Low (3/10). Own PH for durable ~10% earnings compounding plus a growing dividend and the aerospace cycle — not for a fast multibagger. This is a Core-quality business that scores low on exponential precisely because it is already big and mature.
Margins (the real story): gross 37.2% TTM, EBITDA 26.8% TTM, operating ~20.9%, net 16.6% TTM. Segment operating margin hit a record 23.4% in FY26 Q3 (26.7% adjusted). The Win Strategy margin expansion is the durable edge.
Earnings: FY25 net income $3.53B, EPS $27.52 (GAAP); TTM EPS ~$27.58. FY26 Q3 GAAP EPS $7.06 (adjusted $8.17, +18%). Note FY25 Q3 had a one-time $1.37 tax benefit, so GAAP YoY comps look soft — adjusted is the cleaner read.
Cash flow: FY25 operating CF $3.78B, capex −$0.44B, FCF $3.34B (FCF/share ~$29). Year-to-date FY26 operating cash flow a record $2.6B (16.7% of sales). High cash conversion.
Balance sheet: total debt $9.64B, net debt $9.17B, net-debt/EBITDA ~1.6× (down from ~2.5× post-Meggitt), interest coverage 10.8×. Goodwill+intangibles $18.1B (61% of assets) — the M&A-built moat, and a source of tangible-book negativity. Investment-grade and comfortably serviceable.
6. Valuation — priced in or room?
PH is not cheap: 35× trailing EPS, 6.2× sales, 23× EV/EBITDA, 8.3× book. The bull's defense is the usual quality-compounder one — earnings grow into the multiple: forward P/E is ~31× (FY26E) → 28× (FY27E) → 25× (FY28E) → 21× (FY30E). But note the compression is slow here, because EPS only grows ~10%/yr — unlike a hyper-grower where 35× melts to 15× in three years. The PEG (~3.3× forward) confirms you're paying up. FMP's letter grade is B+ (overall score 3/5), dinged specifically on price-to-earnings (2/5) and price-to-book (1/5). Street targets (context): consensus $1,057, high $1,269, low $950 — and today's $963 already sits near the low end of that range implied against fair value. Our $1,010 base FV is a touch below consensus. Bottom line: a wonderful business at a full-to-slightly-rich price — the classic "great company, wait for a better entry" setup.
7. Technicals (from the tech block)
Trend:up. $963 sits above the 50-DMA ($906) and 200-DMA ($886), 50 above 200 (golden-cross posture). MACD +22.6 (positive).
Location:−5.9% off the 52-week high ($1,023), +38% off the 52-week low ($697) — a leadership industrial, modest drawdown (max −5.9% from peak).
Momentum: RSI(14) 67.6 — strong, approaching but not yet overbought (<70). Getting stretched; not a screaming entry.
Relative strength: PH +36.9% 12-mo vs SPY +20.6% — outperforming the market over a year. But note 3-mo +4.6% vs SPY +13.7% and QQQ +22.0% — it has lagged recently as money rotated, and 6-mo is roughly in line with SPY.
Read: technicals are constructive (uptrend, above both DMAs) but momentum is cooling and RSI near 68 argues against chasing here. Consistent with the Watch call — a pullback toward the rising 50-DMA (~$906) would be a lower-risk entry.
8. Moat & competitive position
Parker's moat is breadth + aftermarket + operating system: (1) an unrivaled breadth of motion-and-control SKUs with deep design-in across customer platforms (high switching costs once specified); (2) a large, sticky aftermarket (higher-margin, recurring) distributed through an entrenched channel; (3) The Win Strategy operating discipline that has structurally lifted margins; and (4) a built-up aerospace franchise (LORD, Meggitt) now enjoying a super-cycle with a record $12.5B backlog. Returns confirm quality: ROE ~25%, ROIC ~13%, ROCE ~18%.
Peer set (market cap): the FMP peer list is a mix of quality industrials and aerospace/defense names — Trane Technologies $106B, Illinois Tool Works $78B, Emerson $78B, Cummins $91B, 3M $84B, plus aerospace/defense comps Howmet $108B, GD $101B, Lockheed $126B, Northrop $78B, and ADP $97B. Against the pure industrials (ITW, EMR, TT), PH offers a superior aerospace mix and stronger recent margin momentum; against defense primes it offers commercial-aero and industrial diversification. It commands a premium multiple that only holds if the margin/backlog story persists.
9. Management, capital allocation & guidance
Capital allocation: disciplined and shareholder-friendly — 70 consecutive fiscal years of dividend increases (quarterly dividend just raised 11%), consistent buybacks ($275M repurchased in FY26 Q3), and M&A-led reinvestment (pending Filtration Group, Curtis Instruments) while deleveraging toward ~1.6× net-debt/EBITDA. Cash return + margin expansion is the core value-creation engine.
Insider activity: the sampled Form 4s (filed 2026-04-24) are routine equity awards and associated in-kind tax withholdings for officers (Filtration Group, Aerospace, Digital, HR heads) — compensation mechanics, not open-market discretionary selling. No alarming signal in the sampled window.
Management's own guidance (SEC 8-K, FY26 Q3 release dated 2026-04-30 — half-weighted; management talks its own book): management raised its FY26 (ending June 30, 2026) outlook and now expects mid-teens adjusted EPS growth. Specifics: reported sales growth ~7% (organic +5.5%, acquisitions +1%, divestitures −1%, currency +1.5%); segment operating margin 23.9% (27.2% adjusted); EPS of $27.10 GAAP, $31.20 adjusted. Orders +9%, backlog a record $12.5B. This is a genuine, detailed earnings release with explicit forward guidance — treated at half-weight as management's self-interested framing, but it corroborates the accelerating-aerospace / strong-orders thesis.
10. Catalysts & what to watch
Next earnings: 2026-08-06 (FY26 Q4; Street EPS $8.27, revenue ~$5.57B). The key lines: full-year adjusted EPS vs the $31.20 guide, aerospace organic growth, and order/backlog trajectory.
Aerospace super-cycle: commercial OEM build rates, aftermarket, and defense bookings — the single biggest positive swing factor.
Industrial short-cycle: North America / International organic order rates (currently +6–7%) — the read on whether the broad industrial economy is re-accelerating or rolling over.
Filtration Group acquisition: close timing, price, accretion, and leverage impact — integration execution is the M&A risk.
Margins: whether segment operating margin holds the record ~24% level or gives back in a downturn.
Thesis tripwires (what would change the call): two consecutive quarters of negative industrial order growth; aerospace backlog contraction; a de-rating below ~24× forward (which would flip Watch → Buy on a better entry); or a materially dilutive/over-levered Filtration Group close.
11. Key risks
Industrial cyclicality (structural): roughly two-thirds of revenue is tied to the industrial capex cycle. A recession or destocking wave hits volumes and margins — and lands on a 35× trailing multiple.
Valuation / de-rating: a full multiple on a ~10% EPS grower leaves little margin for error; multiple compression is a real downside vector even if the business is fine.
M&A / leverage: the growth model depends on large acquisitions (Filtration Group pending). Integration missteps, overpayment, or a levered close would pressure returns and the balance sheet.
Aerospace cycle risk: the current aero super-cycle is a tailwind now, but OEM build-rate cuts or a defense-budget shift would remove the one accelerating engine.
No expert corroboration: unlike our conviction-track names, PH has zero independent expert coverage in the Synthos KB — the thesis rests entirely on fundamentals and quant, with no outside qualitative confirmation.
12. Verdict, position sizing & monitoring
Watch. Parker-Hannifin is a genuinely elite industrial — record margins, a 70-year dividend streak, disciplined capital allocation, an accelerating aerospace franchise, and a record backlog. But quality is not the question; price is. At $963 the stock trades essentially at our base-case fair value (~$1,010, +5%) and slightly above where cyclical earnings power comfortably supports it, with a full 35× trailing multiple and momentum cooling (3-mo lagging SPY and QQQ). We would rather own it cheaper.
Sizing (if bought): a ~2–3% cyclical-quality position, ideally scaled in on weakness (toward the rising 50-DMA ~$906 or a broader industrial pullback). Not a chase-here name.
Monitoring: re-underwrite on the §10 tripwires; a de-rating toward ~24× forward or a clean industrial re-acceleration would flip this to Buy. Formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $962.89.
Single biggest risk: industrial cyclicality meeting a full valuation — a downturn would compress both earnings and the multiple at once.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — Parker-Hannifin has no expert coverage in the Synthos knowledge base. This note is fundamentals- and quant-driven; no conviction is borrowed, and no claim_ids are cited because none exist. Fabricated conviction is structurally impossible (claim-ID reconciliation).
Data as-of: fundamentals 2026-03-31 (FY26 Q3) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
Management caveat: the FY26 guidance in §9 is management's own SEC-filed outlook, half-weighted by design (they talk their book).
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").